Document Detail


Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function.
MedLine Citation:
PMID:  22799589     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background and Objective: Boceprevir is a novel inhibitor of the hepatitis C virus NS3 protease and was recently approved for the treatment of patients with chronic hepatitis C infection. The objective of this study was to evaluate the impact of impaired hepatic or renal function on boceprevir pharmacokinetics and safety/tolerability. Methods: We conducted two open-label, single-dose, parallel-group studies comparing the safety and pharmacokinetics of boceprevir in patients with varying degrees of hepatic impairment compared with healthy controls in one study and patients with end-stage renal disease (ESRD) on haemodialysis with healthy controls in the other. Patients with hepatic impairment (mild [n = 6], moderate [n = 6], severe [n = 6] and healthy controls [n = 6]) received a single dose of boceprevir (400 mg) on day 1, and whole blood was collected at selected timepoints up to 72 hours postdose to measure plasma drug concentrations. Patients with ESRD and healthy subjects received a single dose of boceprevir 800 mg orally on days 1 and 4, with samples for pharmacokinetic analyses collected at selected timepoints up to 48 hours postdose on both days. In addition, 4 hours after dosing on day 4, patients with ESRD underwent haemodialysis with arterial and venous blood samples collected up to 8 hours postdose. Results: In the hepatic impairment study, there was a trend toward increased mean maximum (peak) plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC) of boceprevir with increasing severity of liver impairment. Point estimates for the geometric mean ratio for C(max) ranged from 100% in patients with mild hepatic impairment to 161% in patients with severe hepatic impairment, with the geometric mean ratio for AUC ranging from 91% in patients with mild hepatic impairment to 149% for patients with severe hepatic impairment, relative to healthy subjects. The mean elimination half-life (t(½)) and median time to C(max) (t(max)) values of boceprevir were similar in healthy subjects and patients with hepatic impairment. In the renal impairment study, mean boceprevir C(max) and AUC values were comparable in patients with ESRD and in healthy subjects, with point estimates for the geometric mean ratio of 81% and 90%, respectively, compared with healthy subjects. Mean t(½), median t(max) and mean apparent oral total clearance (CL/F) values were similar in healthy subjects and patients with ESRD. Boceprevir exposure was also similar in patients with ESRD on day 1 (no dialysis) and day 4 (dialysis beginning 4 hours postdose), with point estimates for the geometric mean ratio of C(max) and AUC to the last measurable sampling time (AUC(last)) on day 1 compared with day 4 of 88% and 98%, respectively. Treatment-emergent adverse events were reported in one patient with severe hepatic impairment (mild vomiting) and two patients with ESRD (moderate ventricular extrasystoles, flatulence and catheter thrombosis). Conclusion: In the present studies, the pharmacokinetic properties of boceprevir were not altered to a clinically meaningful extent in patients with impaired liver or renal function. These data indicate that boceprevir dose adjustment is not warranted in patients with impaired hepatic function or ESRD, including those receiving dialysis. Boceprevir is not removed by haemodialysis.
Authors:
Michelle Treitel; Thomas Marbury; Richard A Preston; Ilias Triantafyllou; William Feely; Edward O'Mara; Claudia Kasserra; Samir Gupta; Eric A Hughes
Related Documents :
22422079 - Can augmentation index be used as an accurate tool in the diagnosis of peripheral obstr...
21611779 - Prevalence of renal artery stenosis in patients undergoing cardiac catheterization.
11340349 - An intron 4 gene polymorphism in endothelial cell nitric oxide synthase might modulate ...
22223429 - Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with...
22897479 - Hypoalbuminaemia is an independent predictor for hemophagocytic lymphohistiocytosis in ...
21802799 - Malnutrition syndrome, but not body mass index, is associated to worse prognosis in hea...
9783699 - Elevated levels of il-8 in dengue hemorrhagic fever.
21697059 - Peroxisome proliferator receptor (ppar) β/δ in psoriatic patients before and after two ...
22422079 - Can augmentation index be used as an accurate tool in the diagnosis of peripheral obstr...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-16
Journal Detail:
Title:  Clinical pharmacokinetics     Volume:  -     ISSN:  0312-5963     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7606849     Medline TA:  Clin Pharmacokinet     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Merck Sharp Dohme Corp., Whitehouse Station, NJ, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rejected by Peers-Attracted to Antisocial Media Content: Rejection-Based Anger Impairs Moral Judgmen...
Next Document:  Fundamentals of Population Pharmacokinetic Modelling: Validation Methods.